ES2952723T3 - Anticuerpo que reconoce el péptido T14 de AChE - Google Patents
Anticuerpo que reconoce el péptido T14 de AChE Download PDFInfo
- Publication number
- ES2952723T3 ES2952723T3 ES16713029T ES16713029T ES2952723T3 ES 2952723 T3 ES2952723 T3 ES 2952723T3 ES 16713029 T ES16713029 T ES 16713029T ES 16713029 T ES16713029 T ES 16713029T ES 2952723 T3 ES2952723 T3 ES 2952723T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952723T3 true ES2952723T3 (es) | 2023-11-03 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16713029T Active ES2952723T3 (es) | 2015-03-27 | 2016-03-23 | Anticuerpo que reconoce el péptido T14 de AChE |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3274371B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7327897B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102626626B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107531796A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016240020B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017020769A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2979972A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2952723T3 (cg-RX-API-DMAC7.html) |
| GB (2) | GB201505239D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX392158B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2729491C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016156803A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) * | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2546773B (en) * | 2016-01-28 | 2020-06-17 | Neuro Bio Ltd | Cancer |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング,インコーポレイテッド | ガレクチン-3を遮断することにより炎症性疾患を処置する方法 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| EP4584388A1 (en) | 2022-09-08 | 2025-07-16 | Neuro-Bio Ltd | Lateral flow device for diagnosing alzheimer's disease using the t14 peptide |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
| WO2001073446A1 (en) * | 2000-03-29 | 2001-10-04 | Synaptica Limited | Alpha 7 nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| ES2376479T3 (es) * | 2005-08-16 | 2012-03-14 | Genentech, Inc. | Sensibilidad apoptótica a apo2l/trail mediante el ensayo de expresión de galnac-t14 en células y tejidos. |
| GB0708646D0 (en) * | 2007-05-04 | 2007-06-13 | Enkephala Ltd | Biologically active C-terminal fragment of acetylcholinesterase |
| WO2009040789A2 (en) * | 2007-09-24 | 2009-04-02 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 BR BR112017020769A patent/BR112017020769A2/pt active Search and Examination
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2979972A1 (en) | 2016-10-06 |
| EP3274371B1 (en) | 2023-06-07 |
| GB2541477A (en) | 2017-02-22 |
| US10954306B2 (en) | 2021-03-23 |
| CN107531796A (zh) | 2018-01-02 |
| RU2017133649A (ru) | 2019-04-29 |
| AU2016240020B2 (en) | 2022-02-17 |
| JP7327897B2 (ja) | 2023-08-16 |
| WO2016156803A1 (en) | 2016-10-06 |
| AU2016240020A1 (en) | 2017-11-02 |
| KR20170138414A (ko) | 2017-12-15 |
| EP3274371A1 (en) | 2018-01-31 |
| RU2729491C2 (ru) | 2020-08-07 |
| GB201505239D0 (en) | 2015-05-13 |
| BR112017020769A2 (pt) | 2018-06-26 |
| US20180051094A1 (en) | 2018-02-22 |
| KR102626626B1 (ko) | 2024-01-17 |
| MX2017012397A (es) | 2018-01-26 |
| RU2017133649A3 (cg-RX-API-DMAC7.html) | 2020-02-17 |
| JP2018516849A (ja) | 2018-06-28 |
| GB201600871D0 (en) | 2016-03-02 |
| MX392158B (es) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2952723T3 (es) | Anticuerpo que reconoce el péptido T14 de AChE | |
| US11739140B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| US10213506B2 (en) | Targeting immunotherapy for amyloidosis | |
| KR102551971B1 (ko) | 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 | |
| ES2899227T3 (es) | Anticuerpos anti sortilina y métodos de uso de los mismos | |
| KR101831459B1 (ko) | 올리고머 특이적 아밀로이드 베타 에피토프 및 항체 | |
| CN110267985B (zh) | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 | |
| KR20180029205A (ko) | 시누클레인병증의 치료를 위한 제제, 용도 및 방법 | |
| KR20190083356A (ko) | 시누클레인병증의 치료를 위한 제제, 용도 및 방법 | |
| US20120107321A1 (en) | Antibodies And Epitopes Specific To Misfolded Prion Protein | |
| KR20140035337A (ko) | Wnt 조성물 및 이의 사용 방법 | |
| CN107098970A (zh) | 结合细胞内prl‑1多肽或prl‑3多肽的抗体 | |
| US20240279319A1 (en) | Antibody for identifying phosphorylation-specific reactions of threonine at position 1010 of ncapg2, and use thereof | |
| GB2546773A (en) | Cancer |